Tango Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Tango Therapeutics, Inc. carries a market capitalization of 3.78B, placing it among publicly traded companies globally. Its enterprise value stands at 4.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.78B |
| Enterprise Value | 4.28B |
Share Statistics
Tango Therapeutics, Inc. currently has 168.38M shares outstanding.
| Shares Outstanding | 168.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 77.84, and the price-to-book ratio stands at 5.14.
| PE Ratio | N/A |
| PS Ratio | 77.84 |
| PB Ratio | 5.14 |
| P/TBV Ratio | 5.14 |
| P/FCF Ratio | -29.56 |
| P/OCF Ratio | -29.11 |
Enterprise Valuation
| EV / Sales | 79.57 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Tango Therapeutics, Inc. maintains a current ratio of 50.82, meaning it holds 50.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 50.82 |
| Quick Ratio | 49.95 |
| Debt / Equity | 3.12 |
| Debt / EBITDA | -0.24 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -21.34 |
| Return on Assets (ROA) | -18.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -63,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Tango Therapeutics, Inc.'s stock has gained approximately 202.21066% over the past 52 weeks. The 50-day moving average sits at 25.01, while the 200-day moving average is 20.88.
| Beta (5Y) | N/A |
| 52-Week Price Change | 202.21066% |
| 50-Day Moving Average | 25.01 |
| 200-Day Moving Average | 20.88 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Tango Therapeutics, Inc. generated 53.81M in revenue and converted that into -123.72M in net income, yielding earnings per share of -0.91. EBITDA reached -134.42M, while operating income came in at -136.35M.
| Revenue | 53.81M |
| Gross Profit | N/A |
| Operating Income | -136.35M |
| Pretax Income | -123.78M |
| Net Income | -123.72M |
| EBITDA | -134.42M |
| EBIT | -136.35M |
| Earnings Per Share (EPS) | -0.91 |
Balance Sheet
Tango Therapeutics, Inc. holds 1.01B in cash and equivalents against 31.99M in total debt, resulting in a net debt position of -345.56M. Total book value stands at 1.02B, with working capital of 1.01B providing operational flexibility.
| Cash & Cash Equivalents | 1.01B |
| Total Debt | 31.99M |
| Net Debt | -345.56M |
| Equity (Book Value) | 1.02B |
| Book Value Per Share | 6.08 |
| Working Capital | 1.01B |
Cash Flow
Tango Therapeutics, Inc. produced -143.90M in operating cash flow over the past twelve months. After subtracting -373,000.00 in capital expenditures, free cash flow totaled -144.27M - equivalent to -1.08 per share.
| Operating Cash Flow | -143.90M |
| Capital Expenditures | -373,000.00 |
| Free Cash Flow | -144.27M |
| FCF Per Share | -1.08 |
Margins
Tango Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -253.38 and net profit margin of -229.92 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -253.38 |
| Pretax Margin | -230.03 |
| Profit Margin | -229.92 |
| EBITDA Margin | -249.81 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -18.51 |
| FCF Yield | -3.38 |
Scores
Tango Therapeutics, Inc. posts an Altman Z-Score of 63.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 63.84 |